# Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

> **NCT06267560** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 422 (actual)

## Conditions studied

- Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease

## Interventions

- **DRUG:** TQJ230
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06267560
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-24
- **Primary completion:** 2026-03-25
- **Final completion:** 2026-03-25
- **Target enrollment:** 422 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06267560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06267560, "Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06267560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*